cancerres.aacrjournals.org · web viewradi m, evensen l, dreassi e, zamperini c, caporicci m,...

Zebrafish: Speeding up the Cancer Drug Discovery

Process

Patricia Letrado1,2, Irene de Miguel2, Iranzu Lamberto1, Roberto Díez-Martínez1,*

and Julen Oyarzabal2,*

1 Ikan Biotech SL, The Zebrafish Lab Department, Centro Europeo de Empresas e

Innovación de Navarra (CEIN), Plaza CEIN 5 D9-A4, 31110 Noain, Spain.

2 Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for

Applied Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-

31008 Pamplona, Spain.

Table of Contents

S10.1. Supplementary Table S10..............................................................................................S2

S10.2. References S10.................................................................................................................S17

S1

Supplementary Table S10

Aim of the study Subject matter Cancer type Observations RefCompound activity

testingAnti-angigogenic

activity 1

Compound activity testing

Anti-angigogenic activity 2











































S2



activity 24















































Compound activity Anti-angigogenic 48

S3

Aim of the study Subject matter Cancer type Observations Reftesting activity






Anti-angigogenic activity Toxicity assay 51






























Anti-angigogenic activity

Angiogenesis/Toxicity assay 66













S4



activity 73


































Anti-angiogenic activity 90


Anti-lymphagenic activity 91


Anti-lymphagenic activity 92

Compound activity testing Anti-tumoral activity 93




Compound activity Anti-tumoral activity 97

S5

Aim of the study Subject matter Cancer type Observations Reftesting



Compound activity testing Anti-tumoral activity Toxicity assay 100











Specific anti-tumoral activity Many cancer types Toxicity 110


Specific anti-tumoral activity Leukemia Angiogenesis

assay 111


Specific anti-tumoral activity Many cancer types Angiogenesis

assay 112


Specific anti-tumoral activity Pancreatic cancer Xenograft 113


Specific anti-tumoral activity Lung cancer Angiogenesis

assay 114


Specific anti-tumoral activity Hepatocarcinoma Angiogenesis

assay 115


Specific anti-tumoral activity Breat cancer Angiogenesis

assay 116



assay 117



assay 118



assay 119


Specific anti-tumoral activity Many cancer types Xenograft/

Angiogenesis 120



assay 121

S6


testingSpecific anti-tumoral

activity Glioblastoma Xenograft 122


Specific anti-tumoral activity Breast cancer Anngiogenesis

assay 123


Specific anti-tumoral activity Breast cancer 124


Specific anti-tumoral activity Breast cancer Xenograft 125




Specific anti-tumoral activity Leukemia Xenograft 127


Specific anti-tumoral activity Gastric cancer Xenograft 128


Specific anti-tumoral activity Many cancer types 129




Specific anti-tumoral activity Leukemia 131


Specific anti-tumoral activity Melanoma Angiogenesis

assay 132


Specific anti-tumoral activity Myeloma Angiogenesis

assay 133


Specific anti-tumoral activity Melanoma 134










Specific anti-tumoral activity

Hepatocellular carcinoma Xenograft 139


Specific anti-tumoral activity Adenocarcinoma Xenograft 140



assay 141


Specific anti-tumoral activity Glioblastoma Angiogenesis/

Xenograft assay 142



assay 143


Specific anti-tumoral activity Melanoma Angiogesis assay 144



assay 145

Compound activity Specific anti-tumoral Lung cancer Angiogenesis 146

S7

Aim of the study Subject matter Cancer type Observations Reftesting activity assay


Specific anti-tumoral activity Glioma Xenograft 147




Specific anti-tumoral activity Colorrectal 149





assay 151



assay 152



assay 153



assay 154


Specific anti-tumoral activity Colon cancer Angiogenesis

assay 155


Specific anti-tumoral activity Glioblastoma Xenograft 156






Specific anti-tumoral activity Melanoma Xenograft/

Angiogenesis 159




Specific anti-tumoral activity Glioblastoma Xenograft 161


Specific anti-tumoral activity Gliobastoma Xenograft 162





assay 164


Specific anti-tumoral activity Many cancer types Xenograft 165


Specific anti-tumoral activity Myeloma Xenograft 166


Specific anti-tumoral activity Ovarian cancer Angiogenesis/

Xenograft 167


Specific anti-tumoral activity Breast cancer Toxicity assay 168



assay 169



Head and neck squamous cell

Xenograft 170

S8

Aim of the study Subject matter Cancer type Observations Refcarcinoma



assay 171



Embryonal rhabdomyosarcoma 172


Specific anti-tumoral activity Uveal melanoma Xenograft 173


Specific anti-tumoral activity Ewing sarcoma Xenograft 174






Specific anti-tumoral activity Colorectal 177


Specific anti-tumoral activity Colorectal Angiogenesis

assay/ Xenograft 178








Specific anti-tumoral activity Hepatocarcinoma Xenograft 182


Specific anti-tumoral activity Liver cancer Angiogenesis

assay/ Xenograft 183


Specific anti-tumoral activity Lung cancer Xenograft 184





Angiogenesis 186



Malignant rhabdoid tumors Toxicity assay 187



assay 188


Specific anti-tumoral activity Melanoma Xenograft 189


Specific anti-tumoral activity Pancreatic cancer Toxicity assay 190



head and neck squamous cell

carcinoma (HNSCC)Toxicity assay 191





Compound activity Specific anti-tumoral Glioblastoma Xenograft 194

S9



Specific anti-tumoral activity Colon cancer Angiogenesis

assay 195






Specific anti-tumoral activity Colorectal Xenograft 198






Specific anti-tumoral activity Many cancer types Toxicity assay 201


Specific anti-tumoral activity Gastric cancer Angiogenesis

assay 202




Specific anti-tumoral activity Pancreatic cancer Angiogenesis

assay 204



assay 205


Specific anti-tumoral activity Breast cancer Angiogenesis

assay 206






Specific anti-tumoural activity Many cancer types Angiogenesis

assay 209


Specific anti-tumoral activity Oral cancer Angiogenesis

assay 210


Specific anti-tumoral activity Many cancer types Angiogenesis 211



Hepatocellular carcinoma 212



assay 213



assay 214


Specific anti-tumoral activity Lung cancer Xenograft/

Angiogenesis 215


Specific anti-tumoral activity Leukemia Toxicity assay 216




Specific anti-tumoral activity Lewis carcinoma Angiogenesis

assay 218

S10



activity Prostate cancer Toxicity/Xenograft assay 219




Specific anti-tumoral activity Lung cancer Toxicity assay 221





assay 223



assay 224


Specific anti-tumoral activity Lung cancer Toxicity 225


Specific anti-tumoral activity Prostate cancer 226



assay 227



assay 228





assay 230



assay 231





assay 233


Specific anti-tumoral activity Myeloma Xenograft 234



Head and neck cancer Toxicity assay 235


Specific anti-tumoral activity Melanoma Xenograft 236


Specific anti-tumoral activity Breat cancer Angiogenesis

assay 237



assay 238







assay 241



assay 242

Compound activity Specific anti-tumoral Lung cancer 243

S11










Vestibular schwannoma Xenograft 247




Specific anti-tumoral activity Head and neck squamous cell carcinoma 249




Specific anti-tumoral activity Ovarian cancer Xenograft 251



assay 252




Specific anti-tumoral activity Mellanoma 254




Specific anti-tumoral activity Colorectal Toxicity

assay/Xenograft 256


Specific anti-tumoral activity Oral cancer Xenograft 257


Specific anti-tumoral activity Retinoblastoma Xenograft 258



assay 259


Specific anti-tumoral activity Glioblastoma Angiogenesis

assay 260








Specific anti-tumoral activity Colon cancer Toxicity assay 264



assay 265





S12



activity Colorectal Xenograft 268


Specific anti-tumoral activity Prostate cancer Toxicity assay 269


Specific anti-tumoral activity Colorectal 270





Angiogenesis 272


Specific anti-tumoral activity Glioblastoma 273





assay 275


Specific anti-tumoral activity Colon cancer Xenograft 276





assay 278


Specific anti-tumoral activity Prostate cancer Xenograft 279




Specific antitumoral activity Many cancer types Xenograft 281







assay 284





assay 286




Specific anti-tumoral activity Brain tumor Xenograft 288





assay 290



Hepatocellular carcinoma 291

Compound activity Specific anti-tumoral Lung cancer Angiogenesis 292

S13







Specific anti-tumoral activity Cervical cancer Angiogenesis

assay 295








Specific anti-tumoral activity Many cancer types

Xenograft /Angiogenesis

assay 299




Specific anti-tumoral activity Retinoblastoma Xenograft 301



assay 302



assay 303


Specific anti-tumoral activity Lung cancer Angiogenesis/

Toxicity assay 304




Specific anti-tumoral activity Osteosarcoma 306



assay 307




Specific anti-tumoral activity Prostate cancer Xenograft 309


Specific anti-tumoral activity Osteosarcoma Toxicity assay 310


Specific anti-tumoral activity Colorectal Angiogenesis/

Toxicity assay 311









Compound activity Specific anti-tumoral Prostate cancer Angiogenesis 316

S14



Specific anti-tumoral activity Hepatocarcinoma Xenograft 317



assay 318


Specific anti-tumoral activity Ewing sarcoma Xenograft 319




Specific anti-tumoral activity Oral cancer Toxicity assay 321






Specific anti-tumoral activity Ovarian cancer Toxicity assay 324


Specific anti-tumoral activity Glioblastoma Toxicity assay 325



assay 326



Neuroendocrine cancers Xenograft 327

Compound screening Anti-angigogenic activity 328



Compound screening Anti-lymphagenic activity 331

Compound screening Anti-tumoral activity 332Compound screening Anti-tumoral activity 333Compound screening Anti-tumoral activity 334 Compound screening Anti-tumoral activity 335Compound screening Anti-tumoral activity 336Compound screening Anti-tumoral activity 337Compound screening Anti-tumoral activity 338Compound screening Anti-tumoral activity 339Compound screening Anti-tumoral activity 340

Compound screening Specific anti-tumoral activity Leukemia 341

Compound screening Specific anti-tumoral activity Cervical carcinoma 342

Compound screening Specific anti-tumoral activity Leukemia 343

Compound screening Specific anti-tumoral activity

Rhabdomyosarcoma 344

S15

Aim of the study Subject matter Cancer type Observations RefCompound screening Specific anti-tumoral

activity Oral cancer Xenograft 345

Compound screening Specific anti-tumoral activity Melanoma 346


Compound screening Specific anti-tumoral activity

Embryonal rhabdomyosarcoma Xenograft 348


Compound screening Specific anti-tumoral activity Many cancer types Angiogenesis

assay 350

Drug reprofiling Specific anti-tumoral activity Many cancer types Angiogenesis

assay 351

Drug reprofiling Specific anti-tumoral activity Prostate cancer Angiogenesis

assay 352

Drug reprofiling Specific anti-tumoral activity Leukemia 353

Drug reprofiling Specific anti-tumoral activity Melanoma 354

Drug reprofiling Specific anti-tumoral activity Hepatocarcinoma 355

S16

References S10

1. Zhu Z, Zhao Y, Li J, Tao L, Shi P, Wei Z, et al. Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor- mRNA via decreasingα nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol Carcinog 2016;55:1399–410.

2. Zhu W, Fu A, Hu J, Wang T, Luo Y, Peng M, et al. 5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway. Exp Mol Med 2011;43:146–52.

3. Zhou X, Yue GG-L, Liu M, Zuo Z, Zuo Z, Lee JK-M, et al. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling. Oncotarget 2016;7:82820–35.

4. Zhong Z-F, Hoi P-M, Wu G-S, Xu Z-T, Tan W, Chen X-P, et al. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo. J Ethnopharmacol 2012;141:721–7.

5. Zhong H, Lin S. Chemical Screening with Zebrafish Embryos. Methods Mol Biol 2011;716:193–205.

6. Zheng L, Ling P, Wang Z, Niu R, Hu C, Zhang T, et al. A novel polypeptide from shark cartilage with potent anti-angiogenic activity. Cancer Biol Ther 2007;6:775–80.

7. Zhao D, Qin C, Fan X, Li Y, Gu B. Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur J Pharmacol 2014;723:360–7.

8. Zhang S, Li J, Song S, Li J, Tong R, Zang Z, et al. Integrated in silico and experimental methods revealed that Arctigenin inhibited angiogenesis and HCT116 cell migration and invasion through regulating the H1F4A and Wnt/ -catenin pathway.β Mol Biosyst 2015;11:2878–84.

9. Yue GGL, Chan BCL, Kwok H-F, Wong Y-L, Leung H-W, Ji C-J, et al. Anti-angiogenesis and immunomodulatory activities of an anti-tumor sesquiterpene bigelovin isolated from Inula helianthus-aquatica. Eur J Med Chem 2013;59:243–52.

10. Yu X, Tong Y, Kwok H-F, Sze SCW, Zhong L, Lau CB-S, et al. Anti-angiogenic activity of Erxian Decoction, a traditional Chinese herbal formula, in zebrafish. Biol Pharm Bull 2012;35:2119–27.

11. Yang D-S, Peng W-B, Yang Y-P, Liu K-C, Li X-L, Xiao W-L. Chemical constituents from Euphorbia wallichii and their biological activities. J Asian Nat Prod Res 2015;17:946–51.

12. Yang J, He S, Li S, Zhang R, Peng A, Chen L. In Vitro and In Vivo Antiangiogenic Activity of Caged Polyprenylated Xanthones Isolated from Garcinia hanburyi Hook. f. Molecules 2013;18:15305–13.

13. Wu T-M, Wang D-C, Xiang P, Zhang J-N, Sang Y-X, Lin H-J, et al. Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists. Bioorg Med Chem Lett 2014;24:1426–31.

14. Wu X, Zhong H, Song J, Damoiseaux R, Yang Z, Lin S. Mycophenolic acid is a potent inhibitor of angiogenesis. Arterioscler Thromb Vasc Biol 2006;26:2414–6.

15. Wrasidlo W, Mielgo A, Torres VA, Barbero S, Stoletov K, Suyama TL, et al. The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci 2008;105:2313–8.

16. Wang J-J, Chung HY, Zhang Y-B, Li G-Q, Li Y-L, Huang W-H, et al. Diterpenoids from the roots of Croton crassifolius and their anti-angiogenic activity. Phytochemistry 2016;122:270–5.

17. Wang Y, Wang B, Guerram M, Sun L, Shi W, Tian C, et al. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling

S17

through LKB1-AMPK dependent Rho A activatio. Oncotarget 2015;6:29497–512. 18. Wang Z, Liu J, Su A, Sun M, Wang C. Antiangiogenic activity of low-temperature

lysozyme from a marine bacterium in vivo and in vitro. Chinese J Oceanol Limnol 2009;27:835–44.

19. Wang Z, Zheng L, Yang S, Niu R, Chu E, Lin X. N-acetylchitooligosaccharide is a potent angiogenic inhibitor both in vivo and in vitro. Biochem Biophys Res Commun 2007;357:26–31.

20. Vollmer LL, Jimenez M, Camarco DP, Zhu W, Daghestani HN, Balachandran R, et al. A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B-Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos. Mol Cancer Ther 2011;10:994–1006.

21. Tu X, Deng Y, Chen J, Hu Q, He C, Jordan JB, et al. Screening study on the anti-angiogenic effects of Traditional Chinese Medicine – Part I: Heat-clearing and detoxicating TCM. J Ethnopharmacol 2016;194:280–7.

22. Shi L, Zhou J, Wu J, Cao J, Shen Y, Zhou H, et al. Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors. Bioorg Med Chem 2016;24:1840–52.

23. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S, et al. Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis. Cell Metab 2014;19:37–48.

24. Rossette MC, Moraes DC, Sacramento EK, Romano-Silva MA, Carvalho JL, Gomes DA, et al. The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain B. Phyther Res 2017;31:1607–13.

25. Reddy Guduru SK, Chamakuri S, Chandrasekar G, Kitambi SS, Arya P. Tetrahydroquinoline-Derived Macrocyclic Toolbox: The Discovery of Antiangiogenesis Agents in Zebrafish Assay. ACS Med Chem Lett 2013;4:666–70.

26. Radi M, Evensen L, Dreassi E, Zamperini C, Caporicci M, Falchi F, et al. A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. Bioorg Med Chem Lett 2012;22:5579–83.

27. Qi X, Liu G, Qiu L, Lin X, Liu M. Marine bromophenol bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, represses angiogenesis in HUVEC cells and in zebrafish embryos via inhibiting the VEGF signal systems. Biomed Pharmacother 2015;75:58–66.

28. Quezada M, Alvarez M, Peña OA, Henríquez S, d’Alençon CA, Lange S, et al. Antiangiogenic, antimigratory and antiinflammatory effects of 2-methoxyestradiol in zebrafish larvae. Comp Biochem Physiol Part C Toxicol Pharmaco. 2013;157:141–9.

29. Park H, Shim JS, Kim BS, Jung HJ, Huh T-L, Kwon HJ. Purpurin inhibits adipocyte-derived leucine aminopeptidase and angiogenesis in a zebrafish model. Biochem Biophys Res Commun 2014;450:561–7.

30. Papakyriakou A, Kefalos P, Sarantis P, Tsiamantas C, Xanthopoulos KP, Vourloumis D, et al. A Zebrafish In Vivo Phenotypic Assay to Identify 3-Aminothiophene-2-Carboxylic Acid-Based Angiogenesis Inhibitors. Assay Drug Dev Technol 2014;12:527–35.

31. Pan CC, Shah N, Kumar S, Wheeler SE, Cinti J, Hoyt DG, et al. Angiostatic actions of capsicodendrin through selective inhibition of VEGFR2-mediated AKT signaling and disregulated autophagy. Oncotarget 2017;8:12675–85.

32. Nkembo AT, Ntantie E, Salako OO, Amissah F, Poku RA, Latinwo LM, et al. The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget 2016;7:68194–205.

33. Muthukumarasamy KM, Handore KL, Kakade DN, Shinde MV, Ranjan S, Kumar N, et al. Identification of noreremophilane-based inhibitors of angiogenesis using

S18

zebrafish assays. Org Biomol Chem 2016;14:1569–78. 34. Mirando AC, Fang P, Williams TF, Baldor LC, Howe AK, Ebert AM, et al. Aminoacyl-

tRNA synthetase dependent angiogenesis revealed by a bioengineered macrolide inhibitor. Sci Rep 2015;5:13160.

35. Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci 2013;110:12703–8.

36. Ma Q, Wei R, Zhou B, Sang Z, Liu W, Cao Z. Antiangiogenic phenylpropanoid glycosides from Gynura cusimbua. Nat Prod Res 2017;1–7.

37. Lyu J, Yang EJ, Head SA, Ai N, Zhang B, Wu C, et al. Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Cancer Lett 2017;409:91–103.

38. Liu J-X, Luo M-Q, Xia M, Wu Q, Long S-M, Hu Y, et al. Marine Compound Catunaregin Inhibits Angiogenesis through the Modulation of Phosphorylation of Akt and eNOS in vivo and in vitro. Mar Drugs 2014;12:2790–801.

39. Liu G, Liu M, Wei J, Huang H, Zhang Y, Zhao J, et al. CS5931, a Novel Polypeptide in Ciona savignyi, Represses Angiogenesis via Inhibiting Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinases (MMPs). Mar Drugs 2014;12:1530–44.

40. Lintnerová L, García-Caballero M, Gregáň F, Melicherčík M, Quesada AR, Dobiaš J, et al. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis. Eur J Med Chem 2014;72:146–59.

41. Lin C, Wu M, Dong J. Quercetin-4′-O- -D-glucopyranoside (QODG) Inhibitsβ Angiogenesis by Suppressing VEGFR2-Mediated Signaling in Zebrafish and Endothelial Cells. Bunce C, editor. PLoS One 2012;7:e31708.

42. Li P, Yue GG-L, Kwok H-F, Long C, Lau CB-S, Kennelly EJ. Using Ultra-Performance Liquid Chromatography Quadrupole Time of Flight Mass Spectrometry-Based Chemometrics for the Identification of Anti-angiogenic Biflavonoids from Edible Garcinia Species. J Agric Food Chem 2017;65:8348–55.

43. Li J, Peng Y, Li S, Sun Y, Chan JYW, Cui G, et al. Anti-angiogenic activity of a new andrographolide derivative in zebrafish and HUVECs. Eur J Pharmacol 2016;789:344–53.

44. Li K, Liu C, Tam JC, Kwok H, Lau C, Leung P, et al. In vitro and in vivo mechanistic study of a novel proanthocyanidin, GC-(4→8)-GCG from cocoa tea (Camellia ptilophylla) in antiangiogenesis. J Nutr Biochem 2014;25:319–28.

45. Li Y-B, Wang Z-Q, Yan X, Chen M-W, Bao J-L, Wu G-S, et al. IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities. Cancer Lett 2013;340:88–96.

46. Li Y, Wang S-F, Zhao Y-L, Liu K-C, Wang X-M, Yang Y-P, et al. Chemical Constituents from Clematis delavayi var. spinescens. Molecules 2009;14:4433–9.

47. Li X-L, Li Y, Wang S-F, Zhao Y-L, Liu K-C, Wang X-M, et al. Ingol and Ingenol Diterpenes from the Aerial Parts of Euphorbia royleana and Their Antiangiogenic Activities. J Nat Prod 2009;72:1001–5.

48. Lee SH, Lee J, Jung MH, Lee YM. Glyceollins, a novel class of soy phytoalexins, inhibit angiogenesis by blocking the VEGF and bFGF signaling pathways. Mol Nutr Food Res 2013;57:225–34.

49. Lam IK, Alex D, Wang Y-H, Liu P, Liu A-L, Du G-H, et al. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: Identifying sinensetin as a novel antiangiogenesis agent. Mol Nutr Food Res 2012;56:945–56.

50. Lam KH, Alex D, Lam IK, Tsui SKW, Yang ZF, Lee SMY. Nobiletin, a polymethoxylated flavonoid from citrus, shows anti-angiogenic activity in a zebrafish in vivo model and HUVEC in vitro model. J Cell Biochem 2011;112:3313–21.

51. Lai S-L, Cheah S-C, Wong P-F, Noor SM, Mustafa MR. In Vitro and In Vivo Anti-

S19

Angiogenic Activities of Panduratin A. PLoS One 2012;7:e38103.52. Karna P, Rida PCG, Turaga RC, Gao J, Gupta M, Fritz A, et al. A novel microtubule-

modulating agent EM011 inhibits angiogenesis by repressing the HIF-1 axis andα disrupting cell polarity and migration. Carcinogenesis 2012;33:1769–81.

53. Jung MH, Lee SH, Ahn E-M, Lee YM. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis 2009;30:655–61.

54. Jogula S, Dasari B, Khatravath M, Chandrasekar G, Kitambi SS, Arya P. Building a Macrocyclic Toolbox from C -Linked Carbohydrates Identifies Antiangiogenesis Agents from Zebrafish Assay. European J Org Chem 2013;2013:5036–40.

55. Huang B, Peng Y, Li J, Li S, Sun Y, Wang D, et al. An andrographolide derivative AGP-26b exhibiting anti-angiogenic activity in HUVECs and zebrafish via blocking the VEGFA/VEGFR2 signaling pathway. Mol Biosyst 2017;13:525–36.

56. Huang W, Yu X, Liang N, Ge W, Kwok HF, Lau CB-S, et al. Anti-angiogenic Activity and Mechanism of Sesquiterpene Lactones from Centipeda minima. Nat Prod Commun 2016;11:435–8.

57. Huang W, Wang J, Liang Y, Ge W, Wang G, Li Y, et al. Potent anti-angiogenic component in Croton crassifolius and its mechanism of action. J Ethnopharmacol 2015;175:185–91.

58. Hou Y, Chu M, Cai Y, Lei J, Chen Y, ZHU R, et al. Antitumor and anti-angiogenic activity of the recombinant human disintegrin domain of A disintegrin and metalloproteinase 15. Mol Med Rep 2015;12:2360–6.

59. He M-F, Gao X-P, Li S-C, He Z-H, Chen N, Wang Y-B, et al. Anti-angiogenic effect of auranofin on HUVECs in vitro and zebrafish in vivo. Eur J Pharmacol 2014;740:240–7.

60. He S, Lamers GE, Beenakker J-WM, Cui C, Ghotra VP, Danen EH, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol 2012;227:431–45.

61. He Z-H, Ge W, Yue GG-L, Lau CB-S, He M-F, But PP-H. Anti-angiogenic effects of the fruit of Alpinia oxyphylla. J Ethnopharmacol 2010;132:443–9.

62. He MF, Liu L, Ge W, Shaw PC, Jiang R, Wu LW, et al. Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J Ethnopharmacol. 2009;121:61–8.

63. He Z-H, He M-F, Ma S-C, But PP-H. Anti-angiogenic effects of rhubarb and its anthraquinone derivatives. J Ethnopharmacol 2009;121:313–7.

64. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In Vivo Structure−Activity Relationship Study of Dorsomorphin Analogues Identifies Selective VEGF and BMP Inhibitors. ACS Chem Biol 2010;5:245–53.

65. Han L, Yuan Y, Zhao L, He Q, Li Y, Chen X, et al. Tracking antiangiogenic components from Glycyrrhiza uralensisFisch. based on zebrafish assays using high-speed countercurrent chromatography. J Sep Sci 2012;35:1167–72.

66. Garkavtsev I, Chauhan VP, Wong HK, Mukhopadhyay A, Glicksman MA, Peterson RT, et al. Dehydro-alpha-lapachone, a plant product with antivascular activity. Proc Natl Acad Sci 2011;108:11596–601.

67. García-Vilas JA, Pino-Ángeles A, Martínez-Poveda B, Quesada AR, Medina MÁ. The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects. Cancer Lett 2017;385:1–11.

68. García-Caballero M, Cañedo L, Fernández-Medarde A, Medina MÁ, Quesada AR. The marine fungal metabolite, AD0157, inhibits angiogenesis by targeting the Akt signaling pathway. Mar Drugs 2014;12:279–99.

69. García-Caballero M, Marí-Beffa M, Medina MÁ, Quesada AR. Dimethylfumarate Inhibits Angiogenesis In Vitro and In Vivo: A Possible Role for Its Antipsoriatic Effect? J Invest Dermatol 2011;131:1347–55.

70. Fan Y, Peng A, He S, Shao X, Nie C, Chen L. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor

S20

receptor 2 signalling pathway. J Chemother 2013;25:298–308.71. Draut H, Rehm T, Begemann G, Schobert R. Antiangiogenic and Toxic Effects of

Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chem Biodivers 2017;14:e1600302.

72. Dasari B, Jogula S, Borhade R, Balasubramanian S, Chandrasekar G, Kitambi SS, et al. Macrocyclic Glycohybrid Toolbox Identifies Novel Antiangiogenesis Agents from Zebrafish Assay. Org Lett 2013;15:432–5.

73. Cross LM, Cook MA, Lin S, Chen J-N, Rubinstein AL. Rapid Analysis of Angiogenesis Drugs in a Live Fluorescent Zebrafish Assay. Arterioscler Thromb Vasc Biol 2003;23:911–2.

74. Crawford AD, Liekens S, Kamuhabwa AR, Maes J, Munck S, Busson R, et al. Zebrafish Bioassay-Guided Natural Product Discovery: Isolation of Angiogenesis Inhibitors from East African Medicinal Plants. PLoS One 2011;6:e14694.

75. Chimote G, Sreenivasan J, Pawar N, Subramanian J, Sharma S, Sivaramakrishnan H. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy–toxicity model for translational anti-angiogenic drug discovery. Drug Des Devel Ther 2014;8:1107–13.

76. Chen C-H, Durand E, Wang J, Zon LI, Poss KD. Zebraflash Transgenic Lines for in Vivo Bioluminescence Imaging of Stem Cells and Regeneration in Adult Zebrafish. Development 2013;140:4988–97.

77. Chen T, Zhang R-H, He S-C, Xu Q-Y, Ma L, Wang G-C, et al. Synthesis and Antiangiogenic Activity of Novel Gambogic Acid Derivatives. Molecules 2012;17:6249–68.

78. Chan JY-W, Koon JC-M, Liu X, Detmar M, Yu B, Kong S-K, et al. Polyphyllin D, a steroidal saponin from Paris polyphylla, inhibits endothelial cell functions in vitro and angiogenesis in zebrafish embryos in vivo. J Ethnopharmacol 2011;137:64–9.

79. Chan J, Bayliss PE, Wood JM, Roberts TM. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell 2002;1:257–67.

80. Chamakuri S, Guduru SKR, Pamu S, Chandrasekar G, Kitambi SS, Arya P. A Modular Approach to Build Macrocyclic Diversity in Aminoindoline Scaffolds Identifies Antiangiogenesis Agents from a Zebrafish Assay. European J Org Chem 2013;2013:3959–64.

81. Cárdenas C, Quesada AR, Medina MA. Anti-Angiogenic and Anti-Inflammatory Properties of Kahweol, a Coffee Diterpene. PLoS One 2011;6:e23407.

82. Butler CT, Reynolds AL, Tosetto M, Dillon ET, Guiry PJ, Cagney G, et al. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem 2016;292:3552–67.

83. Buchanan CM, Shih J-H, Astin JW, Rewcastle GW, Flanagan JU, Crosier PS, et al. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Clin Sci 2012;122:449–65.

84. Bhanushali U, Kalekar-Joshi S, Kulkarni-Munshi R, Yellanki S. Design, Synthesis and Evaluation of 5-pyridin-4-yl-2-thioxo-[1,3,4]oxadiazol-3-yl Derivatives as Anti-angiogenic Agents Targeting VEGFR-2 | BenthamScience. Anticancer Agents Med Chem 2017;17:67–74. A

85. Beedie SL, Rore HM, Barnett S, Chau CH, Luo W, Greig NH, et al. In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget 2016;7:33237–45.

86. Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, Summers SA, et al. Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood 2007;109:560–5.

87. Alex D, Lam IK, Lin Z, Lee SMY. Indirubin shows anti-angiogenic activity in an in

S21

vivo zebrafish model and an in vitro HUVEC model. J Ethnopharmacol 2010;131:242–7.

88. Alex D, Leong EC, Zhang Z-J, Yan GTH, Cheng S-H, Leong C-W, et al. Resveratrol derivative, trans-3,5,4â€2-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem 2009;109:339–46.

89. Aeluri M, Gaddam J, Trinath DVKS, Chandrasekar G, Kitambi SS, Arya P. An Intramolecular Heck Approach To Obtain 17-Membered Macrocyclic Diversity and the Identification of an Antiangiogenesis Agent from a Zebrafish Assay. European J Org Chem 2013;3955–8.

90. Covassin L, Villefranc J, Kacergis M, Weinstein B, Lawson N. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci 2006;103:6554–9.

91. García-Caballero M, Blacher S, Paupert J, Quesada AR, Medina MA, Noël A. Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway. Br J Pharmacol 2016;173:1966–87.

92. Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, et al. SAR131675, a Potent and Selective VEGFR-3-TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities. Mol Cancer Ther 2012;11:1637–49.

93. Zhong H, Xin S, Zhao Y, Lu J, Li S, Gong J, et al. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish. Mol Biosyst 2010;6:1463–8.

94. Velaithan V, Okuda KS, Ng MF, Samat N, Leong SW, Faudzi SMM, et al. Zebrafish phenotypic screen identifies novel Notch antagonists. Invest New Drugs 2017;35:166–79.

95. Papp D, Kovács T, Billes V, Varga M, Tarnóci A, Hackler L, et al. AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects. Autophagy 2016;12:273–86.

96. Østrup O, Reiner AH, Aleström P, Collas P. The specific alteration of histone methylation profiles by DZNep during early zebrafish development. Biochim Biophys Acta 2014;1839:1307–15.

97. Moro E, Ozhan-Kizil G, Mongera A, Beis D, Wierzbicki C, Young RM, et al. In vivo Wnt signaling tracing through a transgenic biosensor fish reveals novel activity domains. Dev Biol 2012;366:327–40.

98. Lu J, Ma Z, Hsieh J-C, Fan C-W, Chen B, Longgood JC, et al. Structure–activity relationship studies of small-molecule inhibitors of Wnt response. Bioorg Med Chem Lett 2009;19:3825–7.

99. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, et al. Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen Synthase Kinase-3 . J Med Chem 2012;α 55:4407–24.

100. Lisse TS, Middleton LJ, Pellegrini AD, Martin PB, Spaulding EL, Lopes O, et al. Paclitaxel-induced epithelial damage and ectopic MMP-13 expression promotes neurotoxicity in zebrafish. Proc Natl Acad Sci 2016;113:E2189-98.

101. Langheinrich U, Hennen E, Stott G, Vacun G. Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling. Curr Biol 2002;12:2023–8.

102. Kamal A, Shaik AB, Jain N, Kishor C, Nagabhushana A, Supriya B, et al. Design and synthesis of pyrazole-oxindole conjugates targeting tubulin polymerization as new anticancer agents. Eur J Med Chem 2015;92:501–13.

103. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, et al. Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration. Cell 2009;136:1136–47.

104. Fuentes RG, Arai MA, Ishibashi M. Natural compounds with Wnt signal modulating activity. Nat Prod Rep 2015;32:1622–8.

S22

105. Faucherre A, Taylor GS, Overvoorde J, Dixon JE, Hertog J den. Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development. Oncogene 2008;27:1079–86.

106. Ewan K, Pajak B, Stubbs M, Todd H, Barbeau O, Quevedo C, et al. A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Res 2010;70:5963–73.

107. Dulla B, Kirla KT, Rathore V, Deora GS, Kavela S, Maddika S, et al. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties. Org Biomol Chem 2013;11:3103–7.

108. Deng L, Lei Y, Liu R, Li J, Yuan K, Li Y, et al. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis 2013;4:e614.

109. Bugge S, Buene AF, Jurisch-Yaksi N, Moen IU, Skjønsfjell EM, Sundby E, et al. Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties. Eur J Med Chem 2016;107:255–74.

110. Živković MD, Kljun J, Ilic-Tomic T, Pavic A, Veselinović A, Manojlović DD, et al. A new class of platinum(ii) complexes with the phosphine ligand pta which show potent anticancer activity. Inorg Chem Front 2018;5:39–53.

111. Zhou B, Li H, Xing C, Ye H, Feng J, Wu J, et al. Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia. Biochem Pharmacol 2017;128:12–25.

112. Zhou Z, Zhao C, Wang L, Cao X, Li J, Huang R, et al. A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition. Am J Cancer Res 2015;5:3149–61.

113. Zhou R, Curry JM, Roy LD, Grover P, Haider J, Moore LJ, et al. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Oncogene 2016;35:5608–18.

114. Zhong L, Yang J, Cao Z, Chen X, Hu Y, Li L, et al. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget 2017;8:12843–54.

115. Zhong L, Fu X-Y, Zou C, Yang L-L, Zhou S, Yang J, et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. Int J cancer 2014;135:2972–83.

116. Zheng M-W, Zhang C-H, Chen K, Huang M, Li Y-P, Lin W-T, et al. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer. Mol Cancer Ther 2016;15:366–78.

117. Zhao C, Zhang W, Zhao Y, Yang Y, Luo H, Ji G, et al. Endothelial Cords Promote Tumor Initial Growth prior to Vascular Function through a Paracrine Mechanism. Sci Rep 2016;6:1–13.

118. Zhao S, Huang J, Ye J. A fresh look at zebrafish from the perspective of cancer research. J Exp Clin Cancer Res 2015;34:80.

119. Zhao Y-L, Wang S-F, Li Y, He Q-X, Liu K-C, Yang Y-P, et al. Isolation of chemical constituents from the aerial parts of Verbascum thapsus and their antiangiogenic and antiproliferative activities. Arch Pharm Res 2011;34:703–7.

120. Zhao C, Wang X, Zhao Y, Li Z, Lin S, Wei Y, et al. A Novel Xenograft Model in Zebrafish for High-Resolution Investigating Dynamics of Neovascularization in Tumors. PLoS One 2011;6:e21768.

121. Zhao Y-L, He Q-X, Li Y, Wang S-F, Liu K-C, Yang Y-P, et al. Chemical Constituents of Excoecaria acerifolia and Their Bioactivities. Molecules 2010;15:2178–86.

122. Zhao H, Tang C, Cui K, Ang B-T, Wong STC. A screening platform for glioma growth and invasion using bioluminescence imaging. J Neurosurg 2009;111:238–46.

123. Zhang C-H, Chen K, Jiao Y, Li L-L, Li Y-P, Zhang R-J, et al. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1 H -pyrazolo[3,4- d ]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer. J

S23

Med Chem 2016;59:9788–805.124. Zhang J, Liu C, Shi W, Yang L, Zhang Q, Cui J, et al. The novel VEGF receptor 2

inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Oncotarget 2016;7:41067–80.

125. Zhang L, Lu J, Qiu L. Synergistic effects of A-B-C-type amphiphilic copolymer on reversal of drug resistance in MCF-7/ADR breast carcinoma. Int J Nanomedicine 2016;11:5205–20.

126. Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, et al. Development of a Patient-Derived xenofraft (PDX) of breast cancer bone metástasis in a zebrafish model. Int J Mol Sci 2016;17(8):E1375.

127. Zhang B, Shimada Y, Kuroyanagi J, Ariyoshi M, Nomoto T, Shintou T, et al. In vivo selective imaging and inhibition of leukemia stem-like cells using the fluorescent carbocyanine derivative, DiOC5(3). Biomaterials 2015;52:14–25.

128. Zhang Q, Hou D, Luo Z, Chen P, Lv B, Wu L, et al. The novel protective role of P27 in MLN4924-treated gastric cancer cells. Cell Death Dis 2015;6:e1867–e1867.

129. Zhang B, Shimada Y, Kuroyanagi J, Nishimura Y, Umemoto N, Nomoto T, et al. Zebrafish xenotransplantation model for cancer stem-like cell study and high-throughput screening of inhibitors. Tumor Biol. 2014;35:11861–9.

130. Zhang B, Shimada Y, Kuroyanagi J, Umemoto N, Nishimura Y, Tanaka T. Quantitative Phenotyping-Based In Vivo Chemical Screening in a Zebrafish Model of Leukemia Stem Cell Xenotransplantation. PLoS One 2014;9:e85439.

131. Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, et al. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/ -catenin signaling pathway. Blood 2013;121:4906–16.

132. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, et al. SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo. Clin Cancer Res 2011;17:4439–50.

133. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, et al. Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1 -Dependent Pathway in Multiple Myeloma. Cancer Res 2009;69:5082–90.

134. Yue Z, Wang A, Zhu Z, Tao L, Li Y, Zhou L, et al. Holothurian glycosaminoglycan inhibits metastasis via inhibition of P-selectin in B16F10 melanoma cells. Mol Cell Biochem 2015;410:143–54.

135. Yuan Y, Zhao Y, Xin S, Wu N, Wen J, Li S, et al. A Novel PEGylated Liposome-Encapsulated SANT75 Suppresses Tumor Growth through Inhibiting Hedgehog Signaling Pathway. PLoS One 2013;8:e60266.

136. Yeh J-RJ, Munson KM, Chao YL, Peterson QP, Macrae CA, Peterson RT. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 2008;135:401–10.

137. Yee NS, Kazi AA, Yee RK. Translating Discovery in Zebrafish Pancreatic Development to Human Pancreatic Cancer: Biomarkers, Targets, Pathogenesis, and Therapeutics. Zebrafish 2013;10:132–46.

138. Ye Y, Zhang T, Yuan H, Li D, Lou H, Fan P. Mitochondria-Targeted Lupane Triterpenoid Derivatives and Their Selective Apoptosis-Inducing Anticancer Mechanisms. J Med Chem 2017;60:6353–63.

139. Yang J, Pei H, Luo H, Fu A, Yang H, Hu J, et al. Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways. Oncotarget 2017;8:915–32.

140. Yang J, Shimada Y, Olsthoorn RCL, Snaar-Jagalska BE, Spaink HP, Kros A. Application of Coiled Coil Peptides in Liposomal Anticancer Drug Delivery Using a Zebrafish Xenograft Model. ACS Nano 2016;10:7428–35.

141. Yang D-S, Li Z-L, Peng W-B, Yang Y-P, Wang X, Liu K-C, et al. Three new prenylated flavonoids from Macaranga denticulata and their anticancer effects. Fitoterapia 2015;103:165–70.

S24

142. Yang X, Cui W, Yu S, Xu C, Chen G, Gu A, et al. A Synthetic dl-Nordihydroguaiaretic acid (Nordy), Inhibits Angiogenesis, Invasion and Proliferation of Glioma Stem Cells within a Zebrafish Xenotransplantation Model. PLoS One 2014;9:e85759.

143. Yang D-S, Peng W-B, Li Z-L, Wang X, Wei J-G, He Q-X, et al. Chemical constituents from Euphorbia stracheyi and their biological activities. Fitoterapia 2014;97:211–8.

144. Yang J-H, Hu J, Wan L, Chen L-J. Barbigerone inhibits tumor angiogenesis, growth and metastasis in melanoma. Asian Pac J Cancer Prev 2014;15:167–74.

145. Yang L-L, Li G-B, Ma S, Zou C, Zhou S, Sun Q-Z, et al. Structure–Activity Relationship Studies of Pyrazolo[3,4- d ]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and . J Med Chem 2013;56:1641–55.

146. Yang D-S, Peng W-B, Li Z-L, Wang X, Wei J-G, Liu K-C, et al. Chemical constituents from the aerial parts of Euphorbia sikkimensis and their bioactivities. Nat Products Bioprospect 2013;3:112–6.

147. Yang X, Cui W, Gu A, Xu C, Yu S, Li T, et al. A Novel Zebrafish Xenotransplantation Model for Study of Glioma Stem Cell Invasion. PLoS One 2013;8:e61801.

148. Yang X, Chen G, Yu S, Xu C, Xin Y, Li T, et al. TGF- 1 enhances tumor-inducedβ angiogenesis via JNK pathway and macrophage infiltration in an improved zebrafish embryo/xenograft glioma model. Int Immunopharmacol 2013;15:191–8.

149. Yagdi Efe E, Mazumder A, Lee JY, Gaigneaux A, Radogna F, Nasim MJ, et al. Tubulin-binding anticancer polysulfides induce cell death via mitotic arrest and autophagic interference in colorectal cancer. Cancer Lett 2017;410:139–57.

150. Xu J, Zhu X, Qiu L. Polyphosphazene vesicles for co-delivery of doxorubicin and chloroquine with enhanced anticancer efficacy by drug resistance reversal. Int J Pharm 2016;498:70–81.

151. Xu X, Wu Y, Hu M, Li X, Bao Q, Bian J, et al. Novel Natural Product-like Caged Xanthones Bearing a Carbamate Moiety Exhibit Antitumor Potency and Anti-Angiogenesis Activity In vivo. Sci Rep 2016;6:35771.

152. Xu Y, Lin H, Meng N, Lu W, Li G, Han Y, et al. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models. Br J Pharmacol 2013;169:1766–80.

153. Xie L-X, Zhang H-C, Wang H-Y, Wang Y, Wang F-L, Sun J-Y. Two new triterpenoids from Gypsophila oldhamiana. Nat Prod Res 2016;30:1068–74.

154. Xiang W, Ke Z, Zhang Y, Ho-Yuet Cheng G, Irwan ID, Sulochana KN, et al. Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumour growth in mice. J Cell Mol Med 2011;15:359–74.

155. Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, et al. YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models. Sci Rep 2014;4:1–10.

156. Wu J-Q, Zhai J, Li C-Y, Tan A-M, Wei P, Shen L-Z, et al. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. J Exp Clin Cancer Res 2017;36:160.

157. Wu W, Hai Y, Chen L, Liu R-J, Han Y-X, Li W-H, et al. Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity. Pharmacol Res Perspect 2016;4:e00212.

158. Wu S-Y, Wang H-M, Wen Y-S, Liu W, Li P-H, Chiu C-C, et al. 4-(Phenylsulfanyl)butan-2-One Suppresses Melanin Synthesis and Melanosome Maturation In Vitro and In Vivo. Int J Mol Sci 2015;16:20240–57.

159. Wu Q, Deng S, Li L, Sun L, Yang X, Liu X, et al. Biodegradable polymeric micelle-encapsulated quercetin suppresses tumor growth and metastasis in both transgenic zebrafish and mouse models. Nanoscale 2013;5:12480.

160. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, et al. DHODH

S25

modulates transcriptional elongation in the neural crest and melanoma. Nature 2011;471:518–22.

161. Wehmas LC, Tanguay RL, Punnoose A, Greenwood JA. Developing a Novel Embryo–Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics. Zebrafish 2016;13:317–29.

162. Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE. Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech 2016;9:199–210.

163. Wei Z, Shan Y, Tao L, Liu Y, Zhu Z, Liu Z, et al. Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1 synthesis, and decreases breast cancerα metastasis. Mol Carcinog 2017;10: 2317-31.

164. Wei A, Zhou D, Ruan J, Cai Y, Xiong C, Wu G. Anti-tumor and anti-angiogenic effects of Macrothelypteris viridifrons and its constituents by HPLC-DAD/MS analysis. J Ethnopharmacol 2012;139:373–80.

165. Wang J, Kuang B, Guo X, Liu J, Ding Y, Li J, et al. Total Syntheses and Biological Activities of Vinylamycin Analogues. J Med Chem 2017;60:1189–209.

166. Wang G, Zhou P, Chen X, Zhao L, Tan J, Yang Y, et al. The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. Cancer Biol Ther 2017;18:584–95.

167. Wang Y-C, Wu Y-N, Wang S-L, Lin Q-H, He M-F, Liu Q, et al. Docosahexaenoic Acid Modulates Invasion and Metastasis of Human Ovarian Cancer via Multiple Molecular Pathways. Int J Gynecol Cancer 2016;26:994–1003.

168. Wang L, Zhang X, Chan JY-W, Shan L, Cui G, Cui Q, et al. A Novel Danshensu Derivative Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer Cells. J Cell Biochem 2016;117:94–105.

169. Wang L, Zhang J, Cai L, Wen J, Shi H, Li D, et al. Liposomal curcumin inhibits Lewis lung cancer growth primarily through inhibition of angiogenesis. Oncol Lett 2012;4:107–12.

170. von Mässenhausen A, Sanders C, Brägelmann J, Konantz M, Queisser A, Vogel W, et al. Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib. Int J Cancer 2016;139:2359–69.

171. Vogt A, McPherson PA, Shen X, Balachandran R, Zhu G, Raccor BS, et al. High-Content Analysis of Cancer-Cell-Specific Apoptosis and Inhibition of in Vivo Angiogenesis by Synthetic (−)-Pironetin and Analogs. Chem Biol Drug Des 2009;74:358–68.

172 Vleeshouwer-Neumann T, Phelps M, Bammler TK, MacDonald JW, Jenkins I, Chen EY. Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma. PLoS One 2015;10:e0144320.

173. van der Ent W, Burrello C, Teunisse AFAS, Ksander BR, van der Velden PA, Jager MJ, et al. Modeling of Human Uveal Melanoma in Zebrafish Xenograft Embryos. Investig Opthalmology Vis Sci 2014;55:6612–22.

174. van der Ent W, Jochemsen AG, Teunisse AF, Krens SG, Szuhai K, Spaink HP, et al. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. J Pathol 2014;233:415–24.

175. Uckun FM, Tai H-L, D’Cruz OJ. Antileukemic activity and cellular metabolism of the aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07). Arzneimittelforschung 2005;55:50–65.

176. Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 2007;15:800–14.

177. Tumova L, Pombinho AR, Vojtechova M, Stancikova J, Gradl D, Krausova M, et al. Monensin Inhibits Canonical Wnt Signaling in Human Colorectal Cancer Cells and Suppresses Tumor Growth in Multiple Intestinal Neoplasia Mice. Mol Cancer Ther

S26

2014;13:812–22. 178. Fior R, Póvoa V, Mendes RV, Carvalho T, Gomes A, Figueiredo N, et al. Single-cell

functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc Natl Acad USA 2017;114(39):E8234-E8243.

179. Tulotta C, Stefanescu C, Beletkaia E, Bussmann J, Tarbashevich K, Schmidt T, et al. Inhibition of signaling between human CXCR4 and zebrafish ligands by the small molecule IT1t impairs the formation of triple-negative breast cancer early metastases in a zebrafish xenograft model. Dis Model Mech 2016;9:141–53.

180. Tseng C-H, Chen Y-R, Tzeng C-C, Liu W, Chou C-K, Chiu C-C, et al. Discovery of indeno[1,2- b ]quinoxaline derivatives as potential anticancer agents. Eur J Med Chem 2016;108:258–73.

181. Toruń A, Szymańska E, Castanon I, Wolińska-Nizioł L, Bartosik A, Jastrzębski K, et al. Endocytic Adaptor Protein Tollip Inhibits Canonical Wnt Signaling. PLoS One 2015;10:e0130818.

182. Tonon F, Zennaro C, Dapas B, Carraro M, Mariotti M, Grassi G. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing. Int J Pharm 2016;515:583–91.

183. Tian L, Xie K, Sheng D, Wan X, Zhu G. Antiangiogenic effects of oridonin. BMC Complement Altern Med 2017;17:192.

184. Tan DS, Haaland B, Gan J, Tham S, Sinha I, Tan E, et al. Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. Mol Cancer 2014;13:13.

185. Stueven NA, Schlaeger NM, Monte AP, Hwang S-PL, Huang C-C. A novel stilbene-like compound that inhibits melanoma growth by regulating melanocyte differentiation and proliferation. Toxicol Appl Pharmacol 2017;337:30–8.

186. Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S, et al. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010;123:2332–41.

187. Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, et al. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain. Pediatr Blood Cancer 2017;64:1–10.

188. Soomro S, Langenberg T, Mahringer A, Konkimalla VB, Horwedel C, Holenya P, et al. Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties. J Cell Mol Med 2011;15:1122–35.

189. Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, et al. Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. JNCI J Natl Cancer Inst 2013;105:33–46.

190. Sittaramane V, Padgett J, Salter P, Williams A, Luke S, McCall R, et al. Discovery of quinoline-derived trifluoromethyl alcohols, determination of their in vivo toxicity and anticancer activity in a zebrafish embryo model. ChemMedChem 2015;10:1802–7.

191. Shin YS, Cha HY, Lee B-S, Kang SU, Hwang HS, Kwon HC, et al. Anti-cancer Effect of Luminacin, a Marine Microbial Extract, in Head and Neck Squamous Cell Carcinoma Progression via Autophagic Cell Death. Cancer Res Treat 2016;48:738–52.

192. Shin S-H, Lee Y-M. Glyceollins, a novel class of soybean phytoalexins, inhibit SCF-induced melanogenesis through attenuation of SCF/c-kit downstream signaling pathways. Exp Mol Med 2013;45:e17.

193. Sharif GM, Schmidt MO, Yi C, Hu Z, Haddad BR, Glasgow E, et al. Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene 2015;34:5879–89.

194. Schnekenburger M, Goffin E, Lee J-Y, Jang JY, Mazumder A, Ji S, et al. Discovery and Characterization of R / S - N -3-Cyanophenyl- N ′-(6- tert -butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2 H -1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. J

S27

Med Chem 2017;60:4714–33.195. Schmitt F, Gold M, Begemann G, Andronache I, Biersack B, Schobert R. Fluoro and

pentafluorothio analogs of the antitumoral curcuminoid EF24 with superior antiangiogenic and vascular-disruptive effects. Bioorg Med Chem 2017;25:4894–903.

196. Schaefer T, Wang H, Mir P, Konantz M, Pereboom TC, Paczulla AM, et al. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget 2015;6:43540–56.

197. Savio M, Ferraro D, Maccario C, Vaccarone R, Jensen LD, Corana F, et al. Resveratrol analogue 4,4′-dihydroxy-trans-stilbene potently inhibits cancer invasion and metastasis. Sci Rep 2016;6:19973.

198. Roel M, Rubiolo JA, Guerra-Varela J, Silva SBL, Thomas OP, Cabezas-Sainz P, et al. Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model. Oncotarget 2016;7:83071–87.

199. Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BVL, et al. A Small Molecule Inhibitor of PDK1/PLC 1 Interaction Blocks Breast and Melanoma Cancerγ Cell Invasion. Sci Rep 2016;6:26142.

200. Pruvot B, Jacquel A, Droin N, Auberger P, Bouscary D, Tamburini J, et al. Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. Haematologica 2011;96:612–6.

201. Peng Y, Li J, Sun Y, Chan JY-W, Sheng D, Wang K, et al. SAR studies of 3,14,19-derivatives of andrographolide on anti-proliferative activity to cancer cells and toxicity to zebrafish: an in vitro and in vivo study. RSC Adv 2015;5:22510–26.

202. Parng C, Seng WL, Semino C, Mcgrath P. Zebrafish : A Preclinical Model for Drug Screening 2002;1:41–8.

203. Park J-H, Williams DR, Lee J-H, Lee S-D, Lee J-H, Ko H, et al. Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. J Med Chem 2016;59:7410–30.

204. Pan Y, Zheng M, Zhong L, Yang J, Zhou S, Qin Y, et al. A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer. Mol Cancer Ther 2015;14:407–18.

205. Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yang J, et al. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther 2012;11:952–62.

206. Paauwe M, Heijkants RC, Oudt CH, van Pelt GW, Cui C, Theuer CP, et al. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene 2016;35:4069–79.

207. Ouyang L, Zhang L, Liu J, Fu L, Yao D, Zhao Y, et al. Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer. J Med Chem 2017;60:9990–10012.

208 Oo ZM, Illendula A, Grembecka J, Schmidt C, Zhou Y, Esain V, et al. A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF inβ leukemic cells. Leuk Lymphoma 2017;1–13.

209. Oh S-H, Woo JK, Jin Q, Kang H-J, Jeong J-W, Kim K-W, et al. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer 2008;122:5–14.

210. Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, et al. Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget 2015;6:9045–60.

211. Nicoli S, Ribatti D, Cotelli F, Presta M. Mammalian tumor xenograft induce neovascularization in zebrafish embryo. Cancer Res 2007;67:2927–31.

S28

212. Nguyen AT, Emelyanov A, Koh CHV, Spitsbergen JM, Parinov S, Gong Z. An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. Dis Model Mech 2012;5:63–72.

213. Murphy AG, Casey R, Maguire A, Tosetto M, Butler CT, Conroy E, et al. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer. Sci Rep 2016;6:34523.

214. Murphy EA, Shields DJ, Stoletov K, Dneprovskaia E, McElroy M, Greenberg JI, et al. Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci 2010;107:4299–304.

215. Moshal KS, Ferri-Lagneau KF, Haider J, Pardhanani P, Leung T. Discriminating Different Cancer Cells Using a Zebrafish in Vivo Assay. Cancers 2011;3:4102–13.

216. Morash MG, Douglas SE, Robotham A, Ridley CM, Gallant JW, Soanes KH. The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. Dis Model Mech 2011;4:622–33.

217. Mizgirev I V., Revskoy S. A new zebrafish model for experimental leukemia therapy. Cancer Biol Ther 2010;9:895–902.

218. Meta E, Imhof BA, Ropraz P, Fish RJ, Brullo C, Bruno O, et al. The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target. Oncotarget 2017;8:108195–212.

219. Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, et al. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Sci Rep 2017;7:14698.

220. McCall R, Miles M, Lascuna P, Burney B, Patel Z, Sidoran KJ, et al. Dual targeting of the cancer antioxidant network with 1,4-naphthoquinone fused Gold(i) N-heterocyclic carbene complexes. Chem Sci 2017;8:5918–29.

221. Matlapudi M, Moin A, Medishetti R, Rajendra K, Raichur A, Kumar BR. Dual Drug Conjugate Loaded Nanoparticles for the Treatment of Cancer. Curr Drug Deliv 2015;12:782–94.

222. Ma S, Yang L-L, Niu T, Cheng C, Zhong L, Zheng M-W, et al. SKLB-677, an FLT3 and Wnt/ -catenin signaling inhibitor, displays potent activity in models of FLT3-βdriven AML. Sci Rep 2015;5:15646.

223. Ma Y-L, Lin S-W, Fang H-C, Chou K-J, Bee Y-S, Chu T-H, et al. A Novel Poly-Naphthol Compound ST104P Suppresses Angiogenesis by Attenuating Matrix Metalloproteinase-2 Expression in Endothelial Cells. Int J Mol Sci 2014;15:16611–27.

224. Ma L, Chen J, Wang X, Liang X, Luo Y, Zhu W, et al. Structural Modification of Honokiol, a Biphenyl Occurring in Magnolia officinalis: the Evaluation of Honokiol Analogues as Inhibitors of Angiogenesis and for Their Cytotoxicity and Structure–Activity Relationship. J Med Chem 2011;54:6469–81.

225. Lu P, Liu X, Yuan X, He M, Wang Y, Zhang Q, et al. Discovery of a novel NEDD8 Activating Enzyme Inhibitor with Piperidin-4-amine Scaffold by Structure-Based Virtual Screening. ACS Chem Biol 2016;11:1901–7.

226. Lu J, Xin S, Meng H, Veldman M, Schoenfeld D, Che C, et al. A Novel Anti-Tumor Inhibitor Identified by Virtual Screen with PLK1 Structure and Zebrafish Assay. PLoS One 2013;8:e53317.

227. Liu J, Zhu Z, Tang J, Lin Q, Chen L, Sun J. Design and Synthesis of NO-releasing Betulinic Acid Derivatives as Potential Anticancer Agents. Anticancer Agents Med Chem 2017;17:241–9.

228. Liu G, Kuang S, Wu S, Jin W, Sun C. A novel polysaccharide from Sargassum integerrimum induces apoptosis in A549 cells and prevents angiogensis in vitro and in vivo. Sci Rep 2016;6:26722.

229. Liu Y, Zhu P, Wang Y, Wei Z, Tao L, Zhu Z, et al. Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via

S29

Suppressing MMP2/9 by Blocking NF- B and ERK/MAPK Signaling Pathways. PLoSκ One 2015;10:e0123781.

230. Liu L, Yu H, Huang X, Tan H, Li S, Luo Y, et al. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity. BMC Cancer 2015;15:170.

231. Liu Y, Liu Y, Jiang H, Xu L, Cheng Y, Wang PG, et al. Preparation, antiangiogenic and antitumoral activities of the chemically sulfated glucan from Phellinus ribis. Carbohydr Polym 2014;106:42–8.

232. Liu W-S, Kuan Y-D, Chiu K-H, Wang W-K, Chang F-H, Liu C-H, et al. The Extract of Rhodobacter sphaeroides Inhibits Melanogenesis through the MEK/ERK Signaling Pathway. Mar Drugs 2013;11:1899–908.

233. Liu Z, Yuan Q, Zhang X, Xiong C, Xue P, Ruan J. RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1 and inhibition phosphorylation of AKT and mTOR. Cancer Chemotherα Pharmacol 2012;69:1633–40.

234. Lin J, Zhang W, Zhao J-J, Kwart AH, Yang C, Ma D, et al. A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood 2016;128:249–52.

235. Lim YC, Cho KW, Kwon HC, Kang SU, Pyun JH, Lee MH, et al. Growth Inhibition and Apoptosis with H31 Metabolites from Marine Bacillus SW31 in Head and Neck Cancer Cells. Clin Exp Otorhinolaryngol 2010;3:217–25.

236. Liekens S, Noppen S, Gijsbers S, Sienaert R, Ronca R, Tobia C, et al. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget 2015;6:4633–48.

237. Liang N, Li Y, Chung HY. Two natural eudesmane-type sesquiterpenes from Laggera alata inhibit angiogenesis and suppress breast cancer cell migration through VEGF- and Angiopoietin 2-mediated signaling pathways. Int J Oncol 2017;51:213–22.

238. Liang Z, He M, Fong W, Jiang Z, Zhao Z. A comparable, chemical and pharmacological analysis of the traditional Chinese medicinal herbs Oldenlandia diffusa and O. corymbosa and a new valuation of their biological potential. Phytomedicine 2008;15:259–67.

239. Li L, Chen X, Liu CC, Lee LS, Man C, Cheng SH. Phytoestrogen Bakuchiol Exhibits In Vitro and In Vivo Anti-breast Cancer Effects by Inducing S Phase Arrest and Apoptosis. Front Pharmacol 2016;7:128.

240. Li Y, Drabsch Y, Pujuguet P, Ren J, van Laar T, Zhang L, et al. Genetic depletion and pharmacological targeting of v integrin in breast cancer cells impairs metastasis inα zebrafish and mouse xenograft models. Breast Cancer Res 2015;17:28.

241. Li X, Wang X, Ye H, Peng A, Chen L. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways. Cancer Chemother Pharmacol 2012;70:425–37.

242. Li X-L, He Q-X, Zhang F-L, Zhao Y-L, Liu K-C, Jiang S-P. Chemical constituents from Munronia sinica and their bioactivities. Nat Products Bioprospect 2012;2:76–80.

243. Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, et al. In Vivo Validation of PAPSS1 (3’-phosphoadenosine 5’-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target. Clin Cancer Res 2017;23:6555–66.

244. Leong KH, Mahdzir MA, Din MFM, Awang K, Tanaka Y, Kulkeaw K, et al. Induction of intrinsic apoptosis in leukaemia stem cells and in vivo zebrafish model by betulonic acid isolated from Walsura pinnata Hassk (Meliaceae). Phytomedicine 2017;26:11–21.

245. Lenis-Rojas OA, Roma-Rodrigues C, Fernandes AR, Marques F, Pérez-Fernández D, Guerra-Varela J, et al. Dinuclear Ru II (bipy) 2 Derivatives: Structural, Biological, and in Vivo Zebrafish Toxicity Evaluation. Inorg Chem 2017;56:7127–44.

246. Lenis-Rojas OA, Fernandes AR, Roma-Rodrigues C, Baptista P V., Marques F, Pérez-Fernández D, et al. Heteroleptic mononuclear compounds of ruthenium(ii):

S30

synthesis, structural analyses, in vitro antitumor activity and in vivo toxicity on zebrafish embryos. Dalt Trans 2016;45:19127–40.

247. Lee H-J, Yang YJ, Jeong S, Lee JD, Choi S-Y, Jung D-W, et al. Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening. Laryngoscope 2016;126:E409–15.

248. Lee M, Park H, Jeon SW, Bang JK, Chung KY, Choi DW, et al. Novel anti-melanogenic hexapeptoids, PAL-10 and PAL-12. Arch Dermatol Res 2015;307:249–57.

249. Lee B-S, Kang SU, Hwang HS, Kim Y-S, Sung E-S, Shin YS, et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett 2012;322:45–57.

250. Lee SLC, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci 2009;106:19485–90.

251. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 2011;112:2850–64.

252. Kwong W-L, Lam K-Y, Lok C-N, Lai Y-T, Lee P-Y, Che C-M. A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo. Angew Chemie Int Ed 2016;55:13524–8.

253. Kumar KS, Rajesham B, Ramulu MS, Bhaskar B, Dash SN, Ashfaq MA, et al. Cu-Catalyzed ligand-free synthesis of rosuvastatin based novel indole derivatives as potential anticancer agents. RSC Adv 2016;6:100487–93.

254. Kim MK, Bang CY, Kim MY, Lee J-H, Ro H, Choi M-S, et al. Traditional herbal prescription LASAP-C inhibits melanin synthesis in B16F10 melanoma cells and zebrafish. BMC Complement Altern Med 2016;16:223.

255. Kamal A, Reddy VS, Karnewar S, Chourasiya SS, Shaik AB, Kumar GB, et al. Synthesis and Biological Evaluation of Imidazopyridine-Oxindole Conjugates as Microtubule-Targeting Agents. ChemMedChem 2013;8:2015–25.

256. Jung DW, Kim WH, Park SH, Lee J, Kim J, Su D, et al. A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes. ACS Chem Biol 2013;8:1271–82.

257. Jung D-W, Kim J, Che ZM, Oh E-S, Kim G, Eom SH, et al. A Triazine Compound S06 Inhibits Proinvasive Crosstalk between Carcinoma Cells and Stromal Fibroblasts via Binding to Heat Shock Protein 90. Chem Biol 2011;18:1581–90.

258. Jo DH, Son D, Na Y, Jang M, Choi JH, Kim JH, et al. Orthotopic transplantation of retinoblastoma cells into vitreous cavity of zebrafish for screening of anticancer drugs. Mol Cancer 2013;12:71.

259. Jing Y, Wang G, Ge Y, Xu M, Gong Z. Synthesis, Anti-Tumor and Anti-Angiogenic Activity Evaluations of Asiatic Acid Amino Acid Derivatives. Molecules 2015;20:7309–24.

260. Jiang X, Huang Y, Wang X, Liang Q, Li Y, Li F, et al. Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis. Biomed Pharmacother 2017;91:1065–74.

261. Ji S, Lee J-Y, Schrör J, Mazumder A, Jang DM, Chateauvieux S, et al. The dialkyl resorcinol stemphol disrupts calcium homeostasis to trigger programmed immunogenic necrosis in cancer. Cancer Lett 2018;416:109–23.

262. Jelassi B, Anchelin M, Chamouton J, Cayuela ML, Clarysse L, Li J, et al. Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors. Carcinogenesis 2013;34:1487–96.

263. Jang H, Pearce M, O’Donnell E, Nguyen B, Truong L, Mueller M, et al. Identification of a Raloxifene Analog That Promotes AhR-Mediated Apoptosis in Cancer Cells. Biology 2017;6:41.

S31

264. Iman V, Mohan S, Abdelwahab SI, Karimian H, Nordin N, Fadaeinasab M, et al. Anticancer and anti-inflammatory activities of girinimbine isolated fromMurraya koenigii. Drug Des Devel Ther 2017;11:103–21.

265. Hwang SJ, Park H-G, Park Y, Lee H-J. An -quaternary chiral latam derivative, YH-α304 as a novel broad-spectrum anticancer agent. Int J Oncol 2016;49:2480–6.

266. Hung AC, Lo S, Hou M-F, Lee Y-C, Tsai C-H, Chen Y-Y, et al. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clin Cancer Res 2016;22:4478–90.

267. Hsieh T-H, Hsu C-Y, Tsai C-F, Chiu C-C, Liang S-S, Wang T-N, et al. A novel cell-penetrating peptide suppresses breast tumorigenesis by inhibiting -catenin/LEF-1β signaling. Sci Rep 2016;6:19156.

268. Hollenbach M, Stoll SJ, Jörgens K, Seufferlein T, Kroll J. Different Regulation of Physiological and Tumor Angiogenesis in Zebrafish by Protein Kinase D1 (PKD1). PLoS One 2013;8:e68033.

269. Hockey SC, Barbante GJ, Francis PS, Altimari JM, Yoganantharajah P, Gibert Y, et al. A comparison of novel organoiridium(III) complexes and their ligands as a potential treatment for prostate cancer. Eur J Med Chem 2016;109:305–13.

270. Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, et al. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Cancer Cell 2015;28:170–82.

271. He S, Lamers GE, Beenakker J-WM, Cui C, Ghotra VP, Danen EH, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol 2012;227:431–45.

272. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009;12:325–38.

273. Hammarström LGJ, Harmel RK, Granath M, Ringom R, Gravenfors Y, Färnegårdh K, et al. The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features. J Med Chem 2016;59:8577–92.

274. Guo M, Wei H, Hu J, Sun S, LONG J, WANG X. U0126 inhibits pancreatic cancer progression via the KRAS signaling pathway in a zebrafish xenotransplantation model. Oncol Rep 2015;34:699–706.

275. Guan Y-Y, Liu H-J, Luan X, Xu J-R, Lu Q, Liu Y-R, et al. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling. Phytomedicine 2015;22:103–10.

276. Gou M, Men K, Shi H, Xiang M, Zhang J, Song J, et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 2011;3:1558.

277. Göring S, Bensinger D, Naumann EC, Schmidt B. Computer-Guided Design, Synthesis, and Biological Evaluation of Quinoxalinebisarylureas as FLT3 Inhibitors. ChemMedChem 2015;10:511–22.

278. Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, et al. Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression. JNCI J Natl Cancer Inst 2013;105:1188–201.

279. Ghotra VPS, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, et al. SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer. Cancer Res 2015;75:230–40.

280. Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, et al. Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem 2016;59:4697–710.

S32

281. Florean C, Schnekenburger M, Lee J-Y, Kim KR, Mazumder A, Song S, et al. Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. Oncotarget 2016;7:24027–49.

282. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, et al. T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell 2010;18:353–66.

283. Farooq M, Almarhoon ZM, Taha NA, Baabbad AAR, Al-Wadaan MA, El-Faham A. Synthesis of novel class of N-alkyl-isatin-3-iminobenzoic acid derivatives and their biological activity in zebrafish embryos and Human cancer cell lines. Biol Pharm Bull 2018;41:350–359.

284. Farooq M, El-Faham A, Khattab SN, Elkayal AM, Ibrahim MF, Taha NA, et al. Biological screening of novel derivatives of valproic acid for anticancer and antiangiogenic properties. Asian Pacific J Cancer Prev 2014;15:7785–92.

285. Elsayed MSA, Su Y, Wang P, Sethi T, Agama K, Ravji A, et al. Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. J Med Chem 2017;60:5364–76.

286. El-Faham A, Farooq M, Khattab SN, Elkayal AM, Ibrahim MF, Abutaha N, et al. Synthesis and Biological Activity of Schiff Base Series of Valproyl, N-Valproyl Glycinyl, and N-Valproyl-4-aminobenzoyl Hydrazide Derivatives. Chem Pharm Bull 2014;62:591–9.

287. Eguiara A, Holgado O, Beloqui I, Abalde L, Sanchez Y, Callol C, et al. Xenografts in zebrafish embryos as a rapid functional assay for breast cancer stem-like cell identification. Cell Cycle 2011;10:3751–7.

288. Eden CJ, Ju B, Murugesan M, Phoenix T. Orthotopic models of pediatric brain tumors in zebrafish. Oncogene 2015;34:1736–42.

289. Drabsch Y, He S, Zhang L, Snaar-Jagalska BE, ten Dijke P. Transforming growth factor- signalling controls human breast cancer metastasis in a zebrafish xenograftβ model. Breast Cancer Res 2013;15:R106.

290. di Leo N, Battaglini M, Berger L, Giannaccini M, Dente L, Hampel S, et al. A catechin nanoformulation inhibits WM266 melanoma cell proliferation, migration and associated neo-angiogenesis. Eur J Pharm Biopharm 2017;114:1–10.

291. Delgado ER, Yang J, So J, Fanti M, Leimgruber S, Kahn M, et al. Identification and Characterization of a Novel Small-Molecule Inhibitor of -Catenin Signaling. Am Jβ Pathol 2014;184:2111–22.

292. Da-Song Y, Qiu-Xia H, Yong-Ping Y, Ke-Chun L, Xiao-Li L. Chemical constituents of Euphorbia tibetica and their biological activities. Chin J Nat Med 2014;12:38–42.

293. Cosimelli B, Laneri S, Ostacolo C, Sacchi A, Severi E, Porcù E, et al. Synthesis and biological evaluation of imidazo[1,2-a]pyrimidines and imidazo[1,2-a]pyridines as new inhibitors of the Wnt/ -catenin signaling. Eur J Med Chem 2014;β 83:45–56.

294. Corkery DP, Dellaire G, Berman JN. Leukaemia xenotransplantation in zebrafish - chemotherapy response assay in vivo. Br J Haematol 2011;153:786–9.

295. Chu S-C, Yu C-C, Hsu L-S, Chen K-S, Su M-Y, Chen P-N. Berberine Reverses Epithelial-to-Mesenchymal Transition and Inhibits Metastasis and Tumor-Induced Angiogenesis in Human Cervical Cancer Cells. Mol Pharmacol 2014;86:609–23.

296. Christoph S, DeRyckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, et al. UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. Mol Cancer Ther 2013;12:2367–77.

297. Chiu C, Chou H, Chen B, Chang K, Tseng C, Fong Y. BPIQ , a novel synthetic quinoline derivative , inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft model. BMC Cancer 2015;15:962.

298. Chinison J, Aguilar JS, Avalos A, Huang Y, Wang Z, Cameron DJ, et al. Triptonide Effectively Inhibits Wnt/ -Catenin Signaling via C-terminal Transactivation Domainβ of -catenin. Sci Rep 2016;β 6:32779.

S33

299. Cheng J, Gu Y-J, Wang Y, Cheng SH, Wong W-T. Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos. Int J Nanomedicine 2011;6:2007–21.

300. Chen M-C, Zhou B, Zhang K, Yuan Y-C, Un F, Hu S, et al. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro. Mol Pharmacol 2015;87:996–1005.

301. Chen X, Wang J, Cao Z, Hosaka K, Jensen L, Yang H, et al. Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model. Sci Rep 2015;5:10351.

302. Chen X, Liu Y, Yang H-W, Zhou S, CHENG C, ZHENG M-W, et al. SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model. Neoplasma 2014;61:514–22.

303. Chen X, Ji P, Yang H-W, Yang L-L, Zhou S, Zhong L, et al. SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models. Cell Physiol Biochem 2013;32:138–53.

304. Chang D-J, An H, Kim K, Kim HH, Jung J, Lee JM, et al. Design, Synthesis, and Biological Evaluation of Novel Deguelin-Based Heat Shock Protein 90 (HSP90) Inhibitors Targeting Proliferation and Angiogenesis. J Med Chem 2012;55:10863–84.

305. Chaita E, Lambrinidis G, Cheimonidi C, Agalou A, Beis D, Trougakos I, et al. Anti-Melanogenic Properties of Greek Plants. A Novel Depigmenting Agent from Morus alba Wood. Molecules 2017;22:514.

306. Çelik H, Hong S-H, Colón-López DD, Han J, Kont YS, Minas TZ, et al. Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box. Mol Cancer Ther 2015;14:2497–507.

307. Cao Z-X, Zheng R-L, Lin H-J, Luo S-D, Zhou Y, Xu Y-Z, et al. SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo. Cell Physiol Biochem 2011;27:565–74.

308. Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, et al. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clin Cancer Res 2017;23:6215–26.

309. Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget 2017;8:42438–54.

310. Bulut G, Hong S-H, Chen K, Beauchamp EM, Rahim S, Kosturko GW, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012;31:269–81.

311. Bousquet MS, Ma JJ, Ratnayake R, Havre PA, Yao J, Dang NH, et al. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer. ACS Chem Biol 2016;11:1322–31.

312. Bodewein L, Schmelter F, Di Fiore S, Hollert H, Fischer R, Fenske M. Differences in toxicity of anionic and cationic PAMAM and PPI dendrimers in zebrafish embryos and cancer cell lines. Toxicol Appl Pharmacol 2016;305:83–92.

313. Berry JP, Gantar M, Gawley RE, Wang M, Rein KS. Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from a freshwater species of Lyngbya isolated from the Florida Everglades. Comp Biochem Physiol C Toxicol Pharmacol 2004;139:231–8.

314. Benyumov A, Venkatachalam T, Grigoriants O, Vassilev A, Tibbles H, Downs S, et al. Anti-Proliferative and Anti-Leukemic Activity of DDE46 (Compound WHI-07), a Novel Bromomethoxylated Arylphos-phate Derivative of Zidovudine, and Related Compounds. Arzneimittelforschung 2005;55:114–22.

315. Bentley VL, Veinotte CJ, Corkery DP, Pinder JB, Leblanc MA, Bedard K, et al. Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic

S34

platform for T-cell acute lymphoblastic leukemia. Haematologica 2015;100:70–6. 316. Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, et al. Anticancer

Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Mol Cancer Ther 2015;14:2228–37.

317. Bartucci M, Hussein MS, Huselid E, Flaherty K, Patrizii M, Laddha S V., et al. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Target Oncol 2017;12:449–62.

318. Bansode RR, Ahmedna M, Svoboda KR, Losso JN. Coupling in vitro and in vivo paradigm reveals a dose dependent inhibition of angiogenesis followed by initiation of autophagy by C6-ceramide. Int J Biol Sci 2011;7:629–44.

319. Ban J, Aryee DNT, Fourtouna A, van der Ent W, Kauer M, Niedan S, et al. Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma. Cancer Res 2014;74:6578–88.

320. Bagowski CP, You Y, Scheffler H, Vlecken DH, Schmitz DJ, Ott I. Naphthalimide gold(i) phosphine complexes as anticancer metallodrugs. Dalt Trans 2009;48: 10799–10805.

321. Babu PV, Mukherjee S, Deora GS, Chennubhotla KS, Medisetti R, Yellanki S, et al. Ligand/PTC-free intramolecular Heck reaction: synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo. Org Biomol Chem 2013;11:6680–5

322. Astudillo L, Da Silva TG, Wang Z, Han X, Jin K, VanWye J, et al. The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. Cancer Res 2016;76:3593–603.

323. Arumuggam N, Melong N, Too CK, Berman JN, Rupasinghe HV. Phloridzin docosahexaenoate, a novel flavonoid derivative, suppresses growth and induces apoptosis in T-cell acute lymphoblastic leukemia cells. Am J Cancer Res 2017;7:2452–64.

324. Amawi H, Hussein NA, Karthikeyan C, Manivannan E, Wisner A, Williams FE, et al. HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies. Front Pharmacol 2017;8:498.

325. Alexiou GA, Lazari D, Markopoulos G, Vartholomatos E, Hodaj E, Galani V, et al. Moschamine inhibits proliferation of glioblastoma cells via cell cycle arrest and apoptosis. Tumor Biol 2017;39:1–12.

326. Aldawsari FS, Velázquez-Martínez CA. 3,4′,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency. Invest New Drugs 2015;33:775–86.

327. Gaudenzi G, Albertelli M, Dicitore A, Würth R, Gatto F, Barbieri F, et al. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. Endocrine 2017; 57(2):214-219.

328. Tran TC, Sneed B, Haider J, Blavo D, White A, Aiyejorun T, et al. Automated, Quantitative Screening Assay for Antiangiogenic Compounds Using Transgenic Zebrafish. Cancer Res 2007;67:11386–92.

329. Liang F, Han Y, Gao H, Xin S, Chen S, Wang N, et al. Kaempferol Identified by Zebrafish Assay and Fine Fractionations Strategy from Dysosma versipellis Inhibits Angiogenesis through VEGF and FGF Pathways. Sci Rep 2015;5:14468.

330. Camus S, Quevedo C, Menéndez S, Paramonov I, Stouten PFW, Janssen RAJ, et al. Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish. Oncogene 2012;31:4333–42.

331. Astin JW, Jamieson SMF, Eng TCY, Flores M V., Misa JP, Chien A, et al. An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis. Mol Cancer Ther 2014;13:2450–62.

S35

332. Zhong H, Zou H, Semenov M V., Moshinsky D, He X, Huang H, et al. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol Biosyst 2009;5:1356–60.

333. Stern HM, Murphey RD, Shepard JL, Amatruda JF, Straub CT, Pfaff KL, et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat Chem Biol 2005;1:366–70.

334. Robertson JK, Danzmann K, Charles S, Blake K, Olivares A, Bamikole S, et al. Targeting the Wnt pathway in zebrafish as a screening method to identify novel therapeutic compounds. Exp Biol Med 2014;239:169–76.

335. Murphey RD, Stern HM, Straub CT, Zon LI. A Chemical Genetic Screen for Cell Cycle Inhibitors in Zebrafish Embryos. Chem Biol Drug Des 2006;68:213–9.

336. Moon H-S, Jacobson EM, Khersonsky SM, Luzung MR, Walsh DP, Wennan Xiong, et al. A Novel Microtubule Destabilizing Entity from Orthogonal Synthesis of Triazine Library and Zebrafish Embryo Screening. J Am Chem Soc 2002;124:11608–9.

337. Krämer A, Mentrup T, Kleizen B, Rivera-Milla E, Reichenbach D, Enzensperger C, et al. Small molecules intercept Notch signaling and the early secretory pathway. Nat Chem Biol 2013;9:731–8.

338. Hao J, Ao A, Zhou L, Murphy CK, Frist AY, Keel JJ, et al. Selective Small Molecule Targeting -Catenin Function Discovered by In Vivo Chemical Genetic Screen. Cellβ Rep 2013;4:898–904.

339. Geldenhuys WJ, Bergeron SA, Mullins JE, Aljammal R, Gaasch BL, Chen W-C, et al. High-content screen using zebrafish (Danio rerio) embryos identifies a novel kinase activator and inhibitor. Bioorg Med Chem Lett 2017;27:2029–37.

340. Gallardo VE, Varshney GK, Lee M, Bupp S, Xu L, Shinn P, et al. Phenotype-driven chemical screening in zebrafish for compounds that inhibit collective cell migration identifies multiple pathways potentially involved in metastatic invasion. Dis Model Mech 2015;8:565–76.

341. Yeh J-RJ, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 2009;5:236–43.

342. Vrijens K, Lin W, Cui J, Farmer D, Low J, Pronier E, et al. Identification of Small Molecule Activators of BMP Signaling. PLoS One 2013;8:e59045.

343. Ridges S, Heaton WL, Joshi D, Choi H, Eiring A, Batchelor L, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood 2012;119:5621–31.

344. Le X, Pugach EK, Hettmer S, Storer NY, Liu J, Wills AA, et al. A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 2013;140:2354–64.

345. Jung D-W, Oh E-S, Park S-H, Chang Y-T, Kim C-H, Choi S-Y, et al. A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening. Mol Biosyst 2012;8:1930–9.

346. Jung D-W, Williams D, Khershonsky SM, Kang T-W, Heidary N. Identification of the F1F0 mitochondrial ATPase as a target for modulating skin pigmentation by screening a tagged triazine library in zebrafish. Mol Biosyst 2005;1:85–92.

347. Cheng C, Yang H-W, Shang J-F, Li W-W, Sun Q-Z, Chen X, et al. Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro. Melanoma Res 2016;26:117–24.

348. Chen EY, DeRan MT, Ignatius MS, Grandinetti KB, Clagg R, McCarthy KM, et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/ -cateninβ pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci 2014;111:5349–54.

349. Chen L, Ren X, Liang F, Li S, Zhong H, Lin S. Characterization of two novel small molecules targeting melanocyte development in zebrafish embryogenesis. Pigment Cell Melanoma Res 2012;25:446–53.

S36

350. Xiang J, Yang H, Che C, Zou H, Yang H, Wei Y, et al. Identifying Tumor Cell Growth Inhibitors by Combinatorial Chemistry and Zebrafish Assays. PLoS One 2009;4:e4361.

351. Zhu X-Y, Xia B, Liu H-C, Xu Y-Q, Huang C-J, Gao J-M, et al. Closantel Suppresses Angiogenesis and Cancer Growth in Zebrafish Models. Assay Drug Dev Technol 2016;14:282–90.

352. Wang C, Tao W, Wang Y, Bikow J, Lu B, Keating A, et al. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 2010;58:418–26.

353. Gutierrez A, Pan L, Groen RWJ, Baleydier F, Kentsis A, Marineau J, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest 2014;124:644–55.

354. del Ama LF, Jones M, Walker P, Chapman A, Braun JA, Mohr J, et al. Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. Oncotarget 2016;7:40348–61.

355. Evason KJ, Francisco MT, Juric V, Balakrishnan S, Lopez Pazmino M del P, Gordan JD, et al. Identification of Chemical Inhibitors of -Catenin-Driven Liver Tumorigenesisβ in Zebrafish. PLOS Genet 2015;11:e1005305.

S37

cancerres.aacrjournals.org · web viewradi m, evensen l, dreassi e, zamperini c, caporicci m,...

Documents